annual meeting program - American Society of Clinical Oncology

2:00 PM - 6:00 PM
GENERAL POSTER SESSION
Sunday, June 6, 2010
Pediatric Oncology
Location: S Hall A2
Tracks(s): Pediatric Oncology
Brd. 43A Phase I trial of oxaliplatin and doxorubicin in children and adolescents with
recurrent solid tumors. (Abstract #9543)
L. Mascarenhas, S. Armenian, J. L. Harrington, H. Mahmoud, R. Sposto,
M. H. Malogolowkin
Brd. 43B A phase I trial of continuous hyperthermic peritoneal perfusion using
cisplatin in pediatric patients with carcinomatosis. (Abstract #9544)
A. A. Hayes-Jordan, H. L. Green, P. M. Anderson, L. Xiao, K. Hunt, P. F. Mansfield
Brd. 43C Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and
carboplatin (TIC) in children with refractory/recurrent solid tumors.
(Abstract #9545)
A. Lee, C. Handler, L. Harrison, W. V. Shen, L. Gates, R. J. Wells, J. E. Wolff,
J. H. Garvin, D. Yamashiro, M. S. Cairo
Brd. 43D Dose-finding study by continuous reassessment method (CRM) for
topotecan (TT) in combination with ifosfamide (IF) as a second-line therapy
for pediatric solid cancer: Preliminary report of phase I/II study.
(Abstract #9546)
H. Kawamoto, M. Saito, T. Kimura, A. Ogawa, Y. Ishida, T. Taga, H. Mugishima,
A. Makimoto
Brd. 43E An investigator-initiated registration-directed phase I/II clinical trial of
irinotecan hydrochroride for refractory pediatric solid tumors.
(Abstract #9547)
A. Makimoto, H. Mugishima, T. Taga, Y. Ishida, Y. Nagatoshi, K. Ida, M. Kumagai,
T. Kimura, Y. Ohashi, M. Kaneko
Brd. 43F Simulations of cilengitide PK profiles in pediatric population by means of
allometric scaling: Reliability and support to BSA-based dose adjustment
strategy. (Abstract #9548)
M. Zuehlsdorf, M. Campioni, U. Forssmann, A. Munafo, A. Kovar
Brd. 43G Intensity-modulated radiation therapy for pediatric head and neck
rhabdomyosarcoma: French preliminary results. (Abstract #9549)
J. Leseur, V. Bernier, J. Habrand, A. Laprie, M. Mahe, S. Supiot, G. Truc,
E. Le Prisé, L. Claude, C. Carrie
Brd. 43H Sorafenib, gamma-secretase inhibitor, and bortezomib as potential
therapeutic agents for hepatoblastoma. (Abstract #9550)
P. C. Sanchez-Diaz, T. L. Chen, R. Meyers, M. H. Malogolowkin, J. Y. Hung,
G. E. Tomlinson
Brd. 44A Late side effects of neoadjuvant chemotherapy in patients treated for
osteosarcoma and Ewing’s sarcoma: An Italian Sarcoma Group study.
(Abstract #9551)
A. Longhi, C. Ferrari, A. Tamburini, M. Berta, F. Fagioli, G. Bacci, M. Mercuri,
S. Ferrari
Brd. 44B Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with
vincristine, topotecan, and cyclophosphamide in patients with first recurrent
Ewing sarcoma (EWS): A Children’s Oncology Group (COG) study.
(Abstract #9552)
P. Leavey, J. L. Glade Bender, L. Mascarenhas, L. Granowetter, M. Anderson,
M. D. Krailo, R. G. Gorlick, N. Marina
Brd. 44C Long-term results of expandable endoprosthesis replacement in children
with malignant bone tumors. (Abstract #9553)
W. Woz´niak, I. Ługowska, A. Szymborska
277
SUNDAY